Eli Lilly And Company ((LLY)), GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)), CSPC Pharmaceutical Group ((CHJTF)), Elevation Oncology, Inc. ((ELEV)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Elevation Oncology, in collaboration with Eli Lilly, GlaxoSmithKline, and CSPC Pharmaceutical Group, initiated a Phase 1 study titled A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2. The study aimed to evaluate the safety and efficacy of EO-3021 in treating solid tumors expressing CLDN18.2, a protein linked to certain cancers.
The study tested EO-3021 as a monotherapy and in combination with ramucirumab and dostarlimab. EO-3021 is an antibody drug conjugate targeting CLDN18.2, while ramucirumab and dostarlimab are used to inhibit tumor growth pathways.
This non-randomized, open-label study followed a sequential intervention model, focusing on treatment. It aimed to determine the maximum tolerated dose and recommended Phase 2 dose of EO-3021.
The study began on August 10, 2023, but was terminated before completion. The last update was submitted on July 1, 2025. These dates are crucial for understanding the study’s progression and current status.
The termination of this study could impact investor sentiment and stock performance of the involved companies, especially Elevation Oncology, as it may influence their research and development strategies. Competitors in the oncology space might adjust their approaches based on this outcome.
The study has been terminated, and further details can be accessed on the ClinicalTrials portal.